Acorah Software Products - Accounts Production 18.1.200 false true 30 September 2024 1 October 2023 false 1 October 2024 30 September 2025 30 September 2025 07386465 Dr P WARD Mr P GUARD iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 07386465 2024-09-30 07386465 2025-09-30 07386465 2024-10-01 2025-09-30 07386465 frs-core:CurrentFinancialInstruments 2025-09-30 07386465 frs-core:ComputerEquipment 2025-09-30 07386465 frs-core:ComputerEquipment 2024-10-01 2025-09-30 07386465 frs-core:ComputerEquipment 2024-09-30 07386465 frs-core:ShareCapital 2025-09-30 07386465 frs-core:RetainedEarningsAccumulatedLosses 2025-09-30 07386465 frs-bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 07386465 frs-bus:FilletedAccounts 2024-10-01 2025-09-30 07386465 frs-bus:SmallEntities 2024-10-01 2025-09-30 07386465 frs-bus:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 07386465 frs-bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 07386465 frs-bus:Director1 2024-10-01 2025-09-30 07386465 frs-bus:Director2 2024-10-01 2025-09-30 07386465 frs-countries:EnglandWales 2024-10-01 2025-09-30 07386465 2023-09-30 07386465 2024-09-30 07386465 2023-10-01 2024-09-30 07386465 frs-core:CurrentFinancialInstruments 2024-09-30 07386465 frs-core:ShareCapital 2024-09-30 07386465 frs-core:RetainedEarningsAccumulatedLosses 2024-09-30
Registered number: 07386465
PWG CONSULTING (BIOPHARMA) LIMITED
Unaudited Financial Statements
For The Year Ended 30 September 2025
Edmonds Accountancy
PWG CONSULTING (BIOPHARMA) LIMITED
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—4

Page 1
PWG CONSULTING (BIOPHARMA) LIMITED
Balance Sheet
As At 30 September 2025
Balance Sheet
Registered number: 07386465

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Tangible Assets | 4 |  | 1,376 |  | -
|  |  | 1,376 |  | -
CURRENT ASSETS
Debtors | 5 | 2,132 |  | 5,326 |
Cash at bank and in hand |  | 83,421 |  | 138,527 |
|  | 85,553 |  | 143,853 |
Creditors: Amounts Falling Due Within One Year | 6 | (6,235 ) |  | (6,268 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 79,318 |  | 137,585
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 80,694 |  | 137,585
NET ASSETS |  |  | 80,694 |  | 137,585
CAPITAL AND RESERVES
Called up share capital | 8 |  | 100 |  | 100
Profit and Loss Account |  |  | 80,594 |  | 137,485
SHAREHOLDERS' FUNDS |  |  | 80,694 |  | 137,585

Page 1
Page 2
PWG CONSULTING (BIOPHARMA) LIMITED
Balance Sheet (continued)
As At 30 September 2025
For the year ending 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Dr P WARD Director
17/04/2026

The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
PWG CONSULTING (BIOPHARMA) LIMITED
Notes to the Financial Statements
For The Year Ended 30 September 2025
Notes to the Financial Statements
1. General Information
PWG CONSULTING (BIOPHARMA) LIMITED is a private company, limited by shares, incorporated in England & Wales, registered number 07386465 . The registered office is 39 Foxborough, Swallowfield, READING, Berkshire, RG7 1RW.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates,
value added tax and other sales taxes.
Revenue is recognised for the provision of services as the contractual activity progresses.
2.3. Tangible Fixed Assets and Depreciation
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer Equipment | 33% on cost

2.4. Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained
Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
Current or deferred taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or
substantively enacted by the statement of financial position date.
2.5. Pensions
The company operates a defined contribution pension scheme. Contributions payable to the company's pension
scheme are charged to profit or loss in the period to which they relate.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 2 (2024: 2)
2 2
4. Tangible Assets

| Computer Equipment
--- | ---
| £
Cost
As at 1 October 2024 | 5,406
Additions | 2,064
As at 30 September 2025 | 7,470
Depreciation
As at 1 October 2024 | 5,406
Provided during the period | 688
As at 30 September 2025 | 6,094
Net Book Value
As at 30 September 2025 | 1,376
As at 1 October 2024 | -

Page 3
Page 4
PWG CONSULTING (BIOPHARMA) LIMITED
Notes to the Financial Statements (continued)
For The Year Ended 30 September 2025
5. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Trade debtors | 2,092 |  | 3,359
Other debtors | 40 |  | 1,967
| 2,132 |  | 5,326

6. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Other creditors | 6,235 |  | 5,421
Taxation and social security | - |  | 847
| 6,235 |  | 6,268

7. Deferred Taxation
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement
of financial position date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from
those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that
have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the
timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will
be recovered against the reversal of deferred tax liabilities or other future taxable profits.
8. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 100 |  | 100

Page 4